Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUL-042 Safety Study in Hematologic Malignancies
NCT03097796Phase 1Withdrawn
- Sponsor
- Pulmotect
- Start
- Dec 2024
- Primary completion
- Mar 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PUL-042 in respiratory tract infection (RTI), sponsored by Pulmotect. Primary endpoint: Forced Expiratory Volume in one Second at 3 weeks. Planned start Dec 2024; status: withdrawn.
02
Drugs
PUL-042
03
Conditions
respiratory tract infection (RTI)
Beyond the preview
Go deeper on NCT03097796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03097796.